PCM
PGNX

Prelude Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Prelude Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,988
Closed -$15K – 2279
2019
Q4 		$15K Buy
2,988
+2,448
+453% +$12.9K ﹤0.01% 1648
2019
Q3 		$3K Sell
540
-60
-10% -$299 ﹤0.01% 1614
2019
Q2 		$4K Buy
600
+96
+19% +$463 ﹤0.01% 1547
2019
Q1 		$2K Buy
+504
New +$2.28K ﹤0.01% 1697
2018
Q3 		– Sell
-9,656
Closed -$78K – 2179
2018
Q2 		$78K Buy
+9,656
New +$73.7K ﹤0.01% 1005
2017
Q2 		– Sell
-4,023
Closed -$38K – 1978
2017
Q1 		$38K Sell
4,023
-1,077
-21% -$10.7K ﹤0.01% 1122
2016
Q4 		$44K Buy
+5,100
New +$37.7K 0.01% 1081
2015
Q4 		– Sell
-9,239
Closed -$53K – 1787
2015
Q3 		$53K Sell
9,239
-461
-5% -$3.54K 0.01% 1048
2015
Q2 		$72K Sell
9,700
-4,300
-31% -$26K 0.01% 1020
2015
Q1 		$84K Sell
14,000
-6,800
-33% -$42.8K 0.01% 1083
2014
Q4 		$157K Buy
+20,800
New +$124K 0.02% 793
2014
Q2 		– Sell
-3,500
Closed -$14K – 2272
2014
Q1 		$14K Buy
+3,500
New +$17.9K ﹤0.01% 1741

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Prelude Capital Management's PGNX Position: Q1 2020 in Review

Prelude Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 2,988 shares — an estimated $15K sold.

Prelude Capital Management first reported a position in PGNX in Q1 2014 and held it in 12 quarters. The position peaked at $157K in Q4 2014. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Prelude Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 2,988 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $15K.
  • Prelude Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2014 and held it in 12 quarters.
  • Prelude Capital Management's Progenics Pharmaceuticals Inc position peaked at $157K in Q4 2014.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.